Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Unraveling interindividual differences and functional consequences of gut microbial metabolism of critical dose immunosuppressants

ABSTRACT: This study reveals interindividual variability in gut microbial metabolism of immunosuppressive drugs mediated by specific bacterial species and enzymes.

PROVIDER: PRJEB74094 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Interindividual Variability in LPS Responses

Project description:We used an unbiased approach to identify differences in gene expression that may account for the high degree of interindividual variability in inflammatory responses to LPS in the normal human population. We measured LPS-induced cytokine production ex vivo in whole blood from 102 healthy human subjects and identified individuals who consistently showed either very high or very low responses to LPS. Comparison of gene expression profiles between the lpshigh and lpslow individuals revealed 80 genes that were differentially expressed in the presence of LPS and 21 genes that were differentially expressed in the absence of LPS (p < 0.005, ANOVA). Expression of a subset of these genes was confirmed using real-time RT-PCR. These data illustrate a novel approach to the identification of factors that determine interindividual variability in innate immune inflammatory responses. Keywords: comparative response

2005-10-22 | GSE3491 | GEO

Transcription profiling of human lpshigh and lpslow individuals to reveal interindividual variability in LPS responses

2007-09-07 | E-GEOD-3491 | biostudies-arrayexpress

Mechanisms of interindividual epigenetic variability at CpG dense transposable elements

Project description:Mechanisms of interindividual epigenetic variability at CpG dense transposable elements

| PRJNA735220 | ENA

Interindividual comparison of methylation profiling by MSAM

Project description:Interindividual variation in methylation profiling of human DNA samples were detected using two-tissue screening by MSAM. 0.5ug of DNA was serially digested with SmaI and XmaI followed by an adaptor ligation and adaptor mediated PCR amplification HF (hair follicle) and PBL (Peripheral Blood Leukocyte) DNA samples for 8 different individuals, two-color experiment, interindividual paired comparison (same sex and age)

2010-12-01 | E-GEOD-19823 | biostudies-arrayexpress

Interindividual comparison of methylation profiling by MSAM

2010-12-01 | GSE19823 | GEO

Novel enhancer emerge with high interindividual variability and less frequently associate with disease

Project description:Novel enhancer emerge with high interindividual variability and less frequently associate with disease

| PRJNA593966 | ENA

Homo sapiens

Project description:Interindividual Variability in LPS Responses

| PRJNA93313 | ENA

Deciphering Differential Gut Bacterial Drug Metabolism with Activity-Based Protein Profiling

Project description:Gut bacterial β-glucuronidases (GUS) promote the toxic side effects of therapeutics by reactivating drugs from their inactive glucuronide conjugates. It is increasingly clear that the interindividual variability of bacterial GUS-producing species in the gut microbiota contributes to differential drug responses. Indeed, the anticancer drug irinotecan exhibits variable clinical toxicity outcomes that have been linked to interindividual differences in the composition of the gut microbiota. However, identification of the specific GUS enzymes responsible for drug metabolism in the context of the complexity of the human fecal microbiota has not been achieved. Here we pinpoint the specific bacterial GUS enzymes that reactivate SN-38, the active metabolite of irinotecan, from complex human fecal microbiota samples with activity-based protein profiling (ABPP). We identify and quantify gut bacterial GUS enzymes from human feces with ABPP-enabled proteomics and then integrate this information with ex vivo kinetics to reveal the specific GUS enzymes responsible for the reactivation of SN-38. The same ABPP approach also reveals the molecular basis for differential gut bacterial GUS inhibition between human fecal samples. Taken together, this work provides an unprecedented pipeline to identify the specific bacterial GUS enzymes responsible for drug-induced GI toxicity from the complexity of human feces, which may serve as highly precise biomarkers of clinical outcomes for irinotecan and other therapeutics.

2019-12-03 | PXD014864 | Pride

INDIVIDUAL 5-FLUOROURACIL DOSE INDIVIDUALIZATION IN PATIENTS WITH COLORECTAL CANCER

Project description:Primary objectives: 5-fluorouracil (5-FU) is the drug most commonly used in the treatment of patients with colorectal cancer. Its efficacy and toxicity can also be evaluated and predicted according to individual pharmacogenetic (PG), pharmacokinetic (PK) and dynamic data (PD). Individual PK is estimated according to drug plasma concentrations –Cpl and kinetic parameters of 5-FU, mainly the AUC as the measure of exposure to drugs. Clinical outcome which is evaluated according to PD parameters, is more depedent on pharmacokinetics than on the dose. This study is devoted to kinetally guided therapy with 5-FU. Primary endpoints: interindividual variability in pharmacokinetics and dynamics (toxicity)

| 2527156 | ecrin-mdr-crc

Unraveling interindividual differences and functional consequences of gut microbial metabolism of immunosuppressants

Project description:gut microbial metabolism of immunosuppressants

| PRJEB81288 | ENA